Gate2Brain
  • Home
  • Company
    • Mission & vision
    • Awards & Recognitions
    • Seals & Product Designations
    • Supported by
  • About us
    • Founders
    • Team
    • Advisory board
    • Values
  • Technology
    • Scientific Publications
  • Pipeline-Proof of Concept
  • Investors
  • News & Media
  • Contact
  • Menu Menu

Medicines beyond barriers

Video Content
medicines beyond barriersG2B

At Gate2Brain, we have found the key to unlocking the gate to the brain . We have developed a unique shuttle technology to cross the blood-brain barrier. A technology based on a set of peptides to allow the different therapeutic agents to reach the brain in a non-invasive form.

Our first target is pediatric high grades gliomas which is a group of non-curable and fast acting CNS disorders. Gate2Brain’s technology can be applied to other molecules and to other brain diseases. Gate2Brain holds the potential to treat some of the most devastating human diseases.

We are working to bring this technology to the market and go beyond barriers.

 

 

June 29, 2022/by noticias
Tags: Biotech, Innovation, medicinesbeyondbarriers, pediatriccancer, research
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on LinkedIn
  • Share by Mail
https://gate2brain.com/wp-content/uploads/2022/06/Copia-de-EmpresaCultura-CREO.png 1080 1080 noticias https://gate2brain.com/wp-content/uploads/2020/12/Logo-Gate1Brain500pxGrueso.png noticias2022-06-29 10:17:172022-06-29 10:35:02Medicines beyond barriers
You might also like
G2B at Pediatric Diffuse Midline Glioma International Meeting
Plug & Play Biotech Pitch
Many drugs do not reach the brain and Gate2Brain technology helps to overcome that bottleneck
CaixaImpulsGate2Brain as alumni at Caixa Impulse Validate
PaidhosGate2Brain wants to deliver drugs to the brain to combat intact barrier brain tumors, such as DIPG
Innovation & Scalability for the new generationsInnovation & Scalability for the new generations
Sometimes drugs need a bigger push to be more effective and reach their final destination:ExpansionThe drug booster to the brain
Nadia Calviño, First Vice President of the Government and Minister of Economic Affairs visits Gate2BrainSJDNadia Calviño, First Vice President of the Government visits Gate2Brain

CATEGORIES

  • Advisory Board
  • Events
  • Funding & Breakthroughs
  • Interviews
  • Media & Press
  • Media Coverage
  • News
  • Podcasts
  • Press releases
  • Research & Publications
  • Sin categoría
  • Video Content

Events

  • Bioengineering the Future of Drug Delivery workshop – PortoApril 8, 2025 - 10:03
  • Gate2Brain at the 2nd Peptide-Based Therapeutics Summit | BostonMarch 26, 2025 - 15:34
  • 4YFN 2025March 6, 2025 - 19:45
  • Keystone Symposia on Drug Delivery to the Brain: Emerging ModalitiesFebruary 21, 2025 - 11:10
  • Gate2Brain at ACCELERATE 2025: A Decade of Impact and Future Innovations in Pediatric OncologyFebruary 20, 2025 - 10:19

SOCIAL

  • linkedin
  • youtube
Gate2Brain

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We use a radically innovative peptide-based patented technology.

Where to find us

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Social

  • linkedin
  • youtube
© Copyright –Edisenius
  • Privacy Policy
  • Legal Notice
  • Cookie Policy
Gate2Brain semifinalist of EITHealth’s Catapult 2022EITHealth Catapult 2022eithealthGate2Brain participated on June 29 at The Milner Therapeutics Institute (MTI) Pitch Day 🗣️at the University of Cambridge, the cradle of cancer research. The MTI Pitch Day is a great initiative designed to highlight companies like us to investors, to create connections between academic entrepreneurship and investment to promote therapeutic companies. A great event that pulls together on one side academic, preclinical and research and on the other industry in an effort to push forward collaborative drug development and increase the standard of patient careGate2Brain at MIT Pitch Day at University of Cambridge
Scroll to top
Manage Cookie Consent
This Website uses proprietary and third-party cookies to improve services and facilitate browsing. You can obtain further information about the cookies this site uses and how to limit them in the
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
View preferences
{title} {title} {title}